Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice to see Mr Frank purchasing on the open market. 576000 shares total.
Whats up RVVTF board,havent checked in for a while good to still see some old names. Still holding all my shares and crossing fingers that we will at some point in time see some movement,hope everyone has a great week.
News out. Still waiting for phase 2 trial. Ugh. Let the debbie downers comment galore.
https://www.globenewswire.com/news-release/2024/03/12/2844382/0/en/Revive-Therapeutics-Provides-Corporate-Update.html
He buried treasure in the Bahamas for his golf and hooker boon goggle. PPS says it all.
Not at all mate.
Let the like "speak" so the world sees them for what they truly are.
Feb 28 MD&A says it all. End of year only about $708,000 cash on hand and $3.1 million in accounts payable and liabilities. Even if you add in the $2 million from the offering this isn't rocket science, it's simple math. Maybe some of these guys think MF has a money tree in his back yard.
He also should be kicked off the site for that comment
Not at all surprised that comment came from the board poofter!
That’s so absurd people still throwing cash at this trash lol
It looks very promising but in all honesty its about time Revive/MF starts closing on one or more of these targets.
An effective/accurate LC test would be huge IMO but I think i'll hold off on the "celebrations" for the time being.
I'm pretty sure you are the second of 8,000,000,000 to see this news. Thanks for sharing. MF beat you to it.
Has anyone else seen this?
Product: Diagnostic Rapid Test
Indication: Long COVID
Stage of Development: Pre-commercial prototype
Regulatory Status: Preparing submission for FDA approval pathway
https://revivethera.com/wp-content/uploads/2024/02/RVV-Deck-February-2024a.pdf
NEWS: Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110
https://ceo.ca/@GlobeNewswire/revive-therapeutics-ltd-announces-closing-of-the-second
Literally EVERY SINGLE Biotech does exactly that ye gobshite.
Cash is raised based on the potential of the drug/treatment being effective as opposed to being a surety.
Seems you started trading biotechs last week based on the absolutely foolish arguments constantly being made.
There is a strong argument that the purpose of testing is to produce hope, faith, and excitement in order to keep the cash rolling into MF's pocket. This is a cash cow for him and he has all the motivation in the world to milk it as long as he can. You can't tell me this hasn't happened before with penny stock biotechs. In fact it probably happens more often than not with 2 cent biotechs. It's textbook and MF has the perfect motive for doing this....30k per month of shareholder money automatically sent to his bank account. What reason does he have to stop? The longer he strings investors along the more money goes into his pocket...right? It's not rocket science. What has he produced in 4 years? Nothing...absolutely nothing, but how much of your money has he socked away? The writing was on the wall a long time ago and I think most of you see it but just want your money back which is fair, but I question MF's desire to do anything except keep the ball rolling straight to his bank account. That's the only thing he has ever accomplished and it's worked for him. Hence bucillamine 2.0, and he'll keep doing it until the money stops.
Saying "IF" indicates that the company is working on projects like every other Biotech does.
The buccy defense testing and the micro needle patch collaboration are just two examples of said possibilities....not once have I ever indicated that anything was guaranteed hence my continuous usage of "IF".
If Revive had nothing as you claim then there would be no purpose for the testing on the behalf of these external entities eejit.
That said please do regale us some more with this fine display of grammatical idiocy!!!
Yeah. Playing mind games with yourself is not an investment strategy, it's sunk cost fallacy at its fullest.
Yes. Peeps like ric talking themselves into overpaying for an offering. It’s better then being wrong
IF MF can finally finalize some type of deal
could bear fruit at some point.
that sector is still in its infancy
It now all rests on MF being able to finally execute
Nothing....all you got is a bunch of "ifs". Let me spell it out for you Z-E-R-O.
This has been going on nonstop for 4 years now. Where has it gotten the shareholders?
Amazing they are able to raise funds at a premium to market price. Thank goodness only Canadians can get that kind of deal lol
Revive has nothing. You're both right.
Go play yer simple minded word games with your mental midget friends eejit.
I agreed with ye. I said you were right. I thought we kind of bonded on this one.
If thats your assessment of my post then I suggest you go back to school and learn how to read and comprehend what ye read.
Hmmm...it seems to me that Snoop dog said pretty much the same thing you did in your next post. He was just more to the point and did it in a fraction of the words that you did. Revive has nothing. You're both right.
Formalizing the merger would be a solid for Revive……AIMHO
Yes follow. They’re making some solid strides lately. Looking for more solid positioning Q2.
Do you follow Pharmathera?
No i dont. Before the collaboration I saw that both companies were closely linked at the management level.
Still believe as I did back then that there will be a formal merger/consolidation at some point.
AIMHO
Hey Rick! Thank you for your insight. Do you follow Pharmathera? I’ve been invested since .10
The science is now trending away from traditional needles to these types of patches for vaccine delivery.
Several of the usual suspects (Bill Gates etc) have already, or started investing in companies pioneering this tech.
IF MF can finally finalize some type of deal with a large biotech to utilize this patch for drug delivery it could bear fruit at some point.
Stressing on "st some point" since unlike what happened during covid, the days of quick approvals are gone, except for the chosen few of course.
As for the psych end of the business, IMO that sector is still in its infancy as the legislation to legalize its use and the science is still limited in scope.
Contrary to the narrative by the usual suspects, Long Covid isnt going anywhere anytime soon but time is indeed of the essence as Revive is surely not the only company looking into formulating some kind of treatment for the vast numbers of LC sufferers in the USA and Worldwide.
It now all rests on MF being able to finally execute just one, or all of his projects but until that happens I will simply keep a watchful eye and hold.
And yet youre uncontrollably compelled to keep coming here time after time to regurgitate the same tripe.
Would think one would have better things to do with ones valuable time innit!
Wanker!!!
Looks like the scam is still alive. By a time gets approval for long Covid. There won't be a long COVID anymore. Lol They got no data. Just BS. Nothing is coming out of this turd. RS is next. And then start diluting again. ATM pay MF salary.
Still hold some here but I need to get real
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173739479
Still hold some here but I need to get real
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173739479
Anyone looking for 1 more investment emge... mf Sucks if he brought on the guy Bmt wanted pps maybe better lol... hate it bucillamine I know good drug but Chit managed....
I'm just waiting for the R/S.
Is anyone keeping up with progress and what it could mean for 2024 pps?
Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch
February 03, 2023 06:00 ET
| Source: Revive Therapeutics Ltd.
Follow
TORONTO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has entered into a research collaboration agreement with PharmaTher Holdings Ltd. (“PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM) to evaluate the delivery of 3,4-Methylenedioxy?methamphetamine (“MDMA”) using PharmaTher’s novel microneedle patch (“MN-Patch”) delivery technology.
Michael Frank, CEO of the Company, commented, "We are excited about the potential of the MDMA microneedle patch, which will complement our psilocybin programs for mental health and abuse disorders. We look forward to advancing the MDMA patch program that could fill the gaps that we believe could offer an advantage to oral MDMA treatments.”
PharmaTher has completed a non-clinical research study evaluating the delivery of its MDMA MN-Patch. Research results from this study will be available in early Q2-2023 and will be used to support a potential human clinical study. Based on the results, Revive and PharmaTher will finalize a product and clinical development plan to initiate regulatory discussions for future clinical studies in various indications where MDMA may have promise, including depression, anxiety, abuse disorders (i.e. eating, alcohol and drug use), and post-traumatic stress disorder (“PTSD”).
Currently, the nonprofit Multidisciplinary Association for Psychedelic Studies (“MAPS”), through its wholly-owned subsidiary, MAPS Public Benefit Corporation (“MAPS PBC”), has completed two confirmatory Phase 3 trials of MDMA-assisted therapy for PTSD to potentially support its new drug application to be filed with the U.S. Food and Drug Administration (“FDA”) in 1H-2023. The FDA decision for potential approval of MDMA-assisted therapy for PTSD is expected in 2024.
In addition to developing bucillamine for infectious diseases and rare disorders, Revive is building a specialty psychedelics program, which includes psilocybin and MDMA to treat mental health and abuse disorders.
The Company’s psilocybin programs include:
evaluating psilocybin in a Phase 1/2 clinical study for methamphetamine use disorder via a research collaboration with the University of Wisconsin-Madison.
developing a novel psilocybin oral thin film strip through a feasibility agreement with LTS Lohmann Therapie-Systeme AG, a leader in pharmaceutical oral thin films.
developing a novel biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform under its research collaboration with North Carolina State University.
This collaboration will allow Revive to evaluate the results of PharmaTher’s MDMA MN-Patch for indications that do not overlap with the Company’s psilocybin initiatives. The Company believes that the MDMA MN-Patch may enable flexible drug load capacity and combinations, controlled released delivery, and be able to present desired pharmacokinetic and safety profiles which could overcome the potential obstacles of oral dosing.
About the MN-Patch Technology
The microneedle patch delivery technology is based on novel biocompatible and biodegradable gelatin methacryloyl (“GelMA”) material to deliver water-soluble and insoluble drugs with desirable release profiles safely. The GelMA-based microneedle patch can efficiently penetrate the stratum corneum layer (outer layer of the skin), enable flexible drug load capacity and combinations, and control-release delivery. Microneedles are considered a promising way to achieve systemic effects by transdermal delivery of drugs, including psychedelics, and circumventing absorption and first-pass barriers typical for oral delivery. In addition, it aims to empower patients to self-dose safely and incorporates anti-tampering and anti-abuse features.
About PharmaTher Holdings Ltd.
PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is a specialty pharmaceutical company focused on developing and commercializing KETARX™ (racemic ketamine) for mental health, neurological and pain disorders. Learn more at PharmaTher.com.
About Revive Therapeutics Ltd.
Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. With its acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation. For more information, visit ReviveThera.com.
For more information, please contact:
Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release.
The chap makes total sense but unfortunately the worldwide health bureaucracy and drug co. muppets are more interested in developing novel vaccs and drugs instead of focusing more resources on repurposing existing treatments through testing.
Gotta fund the 30k per month salary the shareholders hand to him for playing golf and smoking Cubans. When are the shareholders going to wake up?
Annual offerings lol. MF is a dilution machine
https://finance.yahoo.com/news/revive-therapeutics-ltd-announces-offering-225500147.html
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TO...
Could be a longer slog than was expected but will be worth the wait IMO!
https://revivethera.com/2024/01/revive-therapeutics-provides-update-evaluating-bucillamine-for-nerve-agent-exposure-with-defence-research-and-development-canada/
Two things stand out. One- the short trial timetable: Two- The interest in Bucy as a tool for seizure prevention. Time will tell.
Play the volatility is a good plan. It might take some time but hope you get to even. What a rollercoaster ride this has been.
If, and I say IF, the new formulation proves to be a success and can be monetized, the constant bollocks being spewed here will cease post haste.
As with virtually every Biotech, whether well funded or not, it all hinges on the product being effective.
In case everyone hasn't realized as of yet, this space has, for some time now, reverted to the snail pace (for most that is) that it previously operated under, and by that I mean a ""rigid"" clinical process (again, for most, not all).
This means the wait could be long BUT very profitable IMO for those who held.
Thanks for your ever irrelevant opinion.....stressing on IRRELEVANT!
I've already sold most of my shares and going to take the loss to counter my gains in other stocks. I recently bought more however and have made some of the money back, on paper, in the new year.
With all due respect, the end has already happened my friend. The game is over. The truth is already out. Acceptance is the first step to recovery.
Yada...yada...yada. Same old talk for 4 years now. This company is a scam and you are 100% wrong again. At least your consistent. Now show some real consistency and hold the fantasizers accountable, otherwise you're credibility is dead.
So many nasty posters on here, kind of like the world today. Relax, say your piece but don't tear down others just to make a point. In the end, someone will be right, then the truth will come out.
Followers
|
337
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
36642
|
Created
|
02/23/17
|
Type
|
Free
|
Moderators Classic Warrior |
Scientific Rationale of Bucillamine
Preclinical and clinical studies have demonstrated that reactive oxygen species contribute to the destruction and programmed cell death of pulmonary epithelial cells.1 N-acetyl-cysteine (NAC) has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to restore antioxidant and to reduce the activity of cellular glutathione 2,3,4,5. Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years. Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC 6. The drug is non-toxic with high cellular permeability. The basis of the clinical study will analyze if Bucillamine has the potential, via restoration of glutathione activity and other anti-inflammatory activity, to lessen the negative consequences of SARS-CoV2 infection in the lungs.
| Psilocin Pharma Corp. has developed production solutions for the active compound Psilocybin. Our process encompassed with our intellectual property cover methods of production of Psilocybin based formulations. Psilocin Pharma Corp’s range of products have been engineered to work synergistically with the body's own natural pathways of absorption while offering a contemporary approach to consumption. Psilocin Pharma also has strong relationships with specific lab partners in certain areas like Brazil, where these formulations are legally approved and plan to sell products in these jurisdictions. | |
| |
Mental Health (Depression, PTSD & Anxiety)
|
Supplements for Brain Health & Cognitive Enhancement
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |